EXACT SCIENCES CORP (EXAS) Stock Price & Overview
NASDAQ:EXAS • US30063P1057
Current stock price
The current stock price of EXAS is 104.91 USD. Today EXAS is up by 0.95%. In the past month the price increased by 1.43%. In the past year, price increased by 129.97%.
EXAS Key Statistics
- Market Cap
- 20.026B
- P/E
- N/A
- Fwd P/E
- 345.14
- EPS (TTM)
- -1.03
- Dividend Yield
- N/A
EXAS Stock Performance
EXAS Stock Chart
EXAS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EXAS. When comparing the yearly performance of all stocks, EXAS is one of the better performing stocks in the market, outperforming 95.01% of all stocks.
EXAS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EXAS. While EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability.
EXAS Earnings
On February 13, 2026 EXAS reported an EPS of -0.38 and a revenue of 878.38M. The company missed EPS expectations (-462.34% surprise) and beat revenue expectations (0.03% surprise).
EXAS Forecast & Estimates
29 analysts have analysed EXAS and the average price target is 104.35 USD. This implies a price decrease of -0.54% is expected in the next year compared to the current price of 104.91.
For the next year, analysts expect an EPS growth of 129.51% and a revenue growth 13.66% for EXAS
EXAS Groups
Sector & Classification
EXAS Financial Highlights
Over the last trailing twelve months EXAS reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 81.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.55% | ||
| ROE | -8.66% | ||
| Debt/Equity | 0.97 |
EXAS Ownership
EXAS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EXAS
Company Profile
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 7,100 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Company Info
IPO: 2001-01-30
EXACT SCIENCES CORP
5505 Endeavor Lane
Madison WISCONSIN 53719 US
CEO: Kevin T. Conroy
Employees: 7100
Phone: 16082845700
EXACT SCIENCES CORP / EXAS FAQ
What does EXAS do?
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 7,100 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
What is the stock price of EXACT SCIENCES CORP today?
The current stock price of EXAS is 104.91 USD. The price increased by 0.95% in the last trading session.
What is the dividend status of EXACT SCIENCES CORP?
EXAS does not pay a dividend.
How is the ChartMill rating for EXACT SCIENCES CORP?
EXAS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is EXACT SCIENCES CORP (EXAS) expected to grow?
The Revenue of EXACT SCIENCES CORP (EXAS) is expected to grow by 13.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of EXAS stock?
EXACT SCIENCES CORP (EXAS) has a market capitalization of 20.03B USD. This makes EXAS a Large Cap stock.